SGLT2 inhibitor use and disparities in all-cause mortality in type 2 diabetes: insights from a multi-ethnic population
An erratum to this article was published (Diabetologia, Aug 2026 ↗)
Authors' conclusion
The protective effect of SGLT2i use on mortality appears to differ by ethnicity and is greater in Indigenous Māori and Pacific populations in New Zealand with type 2 diabetes.
Study context
- Population
- Adults aged 18–75 years with T2D in primary care, Auckland/Waikato regions of New Zealand, February 2021 to December 2023; prioritised access for Māori and Pacific people2 matched groups
- Participants
- 59,505 adults
- Exposure
- SGLT2i dispensed vs not dispensed
- SGLT2in = 12,792
- No SGLT2in = 12,792reference
- Outcome
- All-cause mortality by ethnicity, in those with and without CVRD
Methodological detailspropensity-score matched, linked primary care, dispensing and mortality records, Reported in accordance with the CONSIDER statement
- Propensity-score matched
- Linked primary care, dispensing and mortality records
- Reported in accordance with the CONSIDER statement
Main finding
As reported in the abstract
Mortality with SGLT2i use by ethnicity (adjusted)
SGLT2i vs No SGLT2iHazard ratio (95% CI)P value
Māori
0.475(0.336–0.672)
P < 0.001Pacific people
0.507(0.395–0.651)
P < 0.001European people
0.667(0.545–0.816)
P < 0.001Observational data: associations, not effects.
Further findings
Annualised crude mortality (deaths per 1000 individuals per year), with CVRD
Annualised crude mortality (deaths per 1000 individuals per year), without CVRD
Original publication
SGLT2 inhibitor use and disparities in all-cause mortality in type 2 diabetes: insights from a multi-ethnic population. Diabetologia. Published 27 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →